This morning we watched Medpace drop -2.4% to a price of $367.19 per share. The Large-Cap Biotechnology company is now trading -13.15% below its average target price of $422.8. Analysts have set target prices ranging from $340.0 to $480.0 per share for Medpace, and have given the stock an average rating of buy.
Medpace's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.6%. The stock's short ratio is 3.62. The company's insiders own 18.16% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 81.9%. In conclusion, we believe there is positive market sentiment regarding Medpace.
Institutions Invested in Medpace
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-12-31 | Vanguard Group Inc | 8% | 2,556,443 | $938,700,311 |
| 2023-12-31 | Blackrock Inc. | 8% | 2,418,056 | $887,885,988 |
| 2024-03-31 | Wasatch Advisors LP | 3% | 974,415 | $357,795,446 |
| 2023-12-31 | Invesco Ltd. | 2% | 723,238 | $265,565,762 |
| 2023-12-31 | Riverbridge Partners LLC | 2% | 683,943 | $251,137,031 |
| 2023-12-31 | State Street Corporation | 2% | 671,145 | $246,437,734 |
| 2023-12-31 | Geode Capital Management, LLC | 2% | 492,931 | $180,999,335 |
| 2023-12-31 | TD Asset Management, Inc | 2% | 467,041 | $171,492,785 |
| 2023-12-31 | Fuller & Thaler Asset Management Inc. | 1% | 444,738 | $163,303,347 |
| 2023-12-31 | Wellington Management Group, LLP | 1% | 414,568 | $152,225,224 |
